Dr. Samip R. Master, MBBS
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 275
Licensed in Texas since 2024, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license V1835 (first issued 2024; active) · LA license MD.207162
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Texas Medical Branch Galveston Galveston, TX
- HCA Houston Healthcare Clear Lake Webster, TX
- HCA Houston Healthcare Southeast Pasadena, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 275
- Services billed
- 1,575
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 367 | 177 |
| Established patient office or other outpatient visit, 40-54 minutes | 235 | 84 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 120 | 45 |
| Established patient office or other outpatient visit, 20-29 minutes | 89 | 64 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 70 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 35 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 32 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
| New patient office or other outpatient visit, 30-44 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Webster, TX | 111 |
| Prednisone Other prescribers in Webster, TX | 89 |
| Ondansetron Odt (ondansetron) Other prescribers in Webster, TX | 63 |
| Acyclovir Other prescribers in Webster, TX | 46 |
| Abiraterone Acetate | 42 |
| Revlimid (lenalidomide) | 40 |
| Oxycodone Hcl Other prescribers in Webster, TX | 34 |
| Promethazine Hcl Other prescribers in Webster, TX | 31 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Webster, TX | 31 |
| Eliquis (apixaban) Other prescribers in Webster, TX | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 66 payments worth $4,128 in total to this clinician.
| Janssen Biotech, Inc. | $2,522 |
|---|---|
| AbbVie Inc. | $559 |
| Novartis Pharmaceuticals Corporation | $138 |
| Seagen Inc. | $99.00 |
| AstraZeneca Pharmaceuticals LP | $81.81 |
| Merck Sharp & Dohme LLC | $65.27 |
| Genmab U.S., Inc. | $56.18 |
| Pfizer Inc. | $55.86 |
| Consulting Fee | $2,025 |
|---|---|
| Food and Beverage | $1,719 |
| Travel and Lodging | $285 |
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Sep 11, 2025 | Consulting Fee DARZALEX · Oncology | $2,025 |
| Janssen Biotech, Inc. Sep 4, 2025 | Travel and Lodging DARZALEX · Oncology · travel to HOUSTON, TX · in-kind | $259 |
| Seagen Inc. Mar 28, 2025 | Education in-kind | $99.00 |
| Janssen Biotech, Inc. Sep 4, 2025 | Travel and Lodging DARZALEX · Oncology · travel to HOUSTON, TX | $26.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $15,500 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie Inc. · Recruiting · NCT06428019
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.